Skip to main content
Subscribe
Register
Sign in
Membership
Events
Knowledge Center
About
Subscribe
Register
Sign in
Premium
Alternative Insight and Premium Journalism
Latest Articles
Casdin Capital Leads a Strong Month for Biopharma Funds
Steve Taub
November 13, 2024
Viking’s Private Company Investments Turn Profitable
Steve Taub
November 12, 2024
Icahn’s Private Hedge Fund Posts a Quarterly Gain — But Is Still in the Red
Steve Taub
November 11, 2024
Macro Fund Haidar Jupiter Rings Up More Losses
Steve Taub
November 7, 2024
Dan Loeb’s Hedge Fund Is Within Striking Distance of Its Best Results Since 2021
Steve Taub
November 6, 2024
The Tiger Grandcub Headed by Glen Kacher Maintains Its Status as a Top Performer This Year
Steve Taub
November 5, 2024
Greenlight Gets Off to a Good Start in the Fourth Quarter
Steve Taub
November 4, 2024
Biopharma IPOs Have Surged. Will Tech Follow?
Steve Taub
October 31, 2024
Hedgies Brace for Magnificent Seven Earnings Reports
Steve Taub
October 30, 2024
Former Citadel Equity Pros Run Fund That Has Been Profitable Every Quarter Since Its Start
Steve Taub
October 29, 2024
Bears Bemoan Tesla Surge
Steve Taub
October 28, 2024
Why These Tiger Funds Continue to Outpace the Market
Steve Taub
October 24, 2024
Janus Henderson Maintains Its Wide Lead in Biotech
Steve Taub
October 23, 2024
Lone Pine Makes Back Earlier Losses
Steve Taub
October 22, 2024
Loeb Bullish on a Republican Win
Stephen Taub
October 21, 2024
Top Performing Averill Partners Closes to New Investors
Steve Taub
October 17, 2024
Einhorn: “We Are Likely to Underperform”
Steve Taub
October 16, 2024
D1 Capital’s Dan Sundheim Makes Changes After Two Consecutive Knockdowns
Steve Taub
October 15, 2024
More Articles